Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06544499 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
A Phase 3 study of Primary Immune Thrombocytopenia (ITP), sponsored by argenx.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 69
- Enrollment target
- 20
- Study locations
NCT06544499 is a Phase 3 study of Primary Immune Thrombocytopenia (ITP) that is actively recruiting participants, run by argenx. The registered enrollment target is 69 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT06544499, a Phase 3 study of Primary Immune Thrombocytopenia (ITP), is actively recruiting participants, sponsored by argenx.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 69 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first 52-week open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second 52-week OLTP2. After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks. More information can be found here: https://clinicaltrials.argenx.com/advancenext
Conditions Studied
Interventions
- BIOLOGICAL Efgartigimod IV
- OTHER Placebo IV
Study Locations (20)
California
- University of Southern California Norris Comprehensive Cancer Center - Los Angeles
- Sharp Memorial Hospital - Oceanside
North Carolina
- Duke University Medical Center - Durham
- Brody School of Medicine at East Carolina University - Greenville
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- Ohio State University Hospital East - Columbus
Other
- Allgemeines Krankenhaus der Stadt Linz - Linz
- Ordensklinikum Linz GmbH Elisabethinen - Linz
Arizona
- Mayo Clinic Hospital Scottsdale - Phoenix
Colorado
- University of Colorado Hospital - Aurora
Connecticut
- Yale University School of Medicine - New Haven
District of Columbia
- Georgetown University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2024-10-18 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06544499
The ClinicalTrials.gov registry entry for NCT06544499 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Immune Thrombocytopenia (ITP) appearing as the primary indexed condition, and to 2 interventions - of which Efgartigimod IV is the first listed.
NCT06544499 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT06544499 about?
NCT06544499 is a clinical study titled "A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia". The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo I...
What is the current status of trial NCT06544499?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 69 participants. The study started on 2024-10-18. Estimated completion is 2028-06.
What conditions does trial NCT06544499 study?
This clinical trial studies the following conditions: Primary Immune Thrombocytopenia (ITP).
What interventions are being tested in trial NCT06544499?
The interventions under investigation include: Efgartigimod IV (BIOLOGICAL), Placebo IV (OTHER).
Who is sponsoring clinical trial NCT06544499?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06544499 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Immune Thrombocytopenia (ITP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.